Literature DB >> 8959418

Continuation rates among injectable contraceptive users.

J M Westfall1, D S Main, L Barnard.   

Abstract

Few published data exist on the ongoing use of depot medroxyprogesterone acetate, the injectable contraceptive. Women who obtained the injectable from Planned Parenthood of the Rocky Mountains between January 1993 and March 1995 were followed to ascertain continuation rates for the method. Of the 5,178 women who received an initial injection, only 57% returned for a second administration; 63% of those who returned for their second injection went on to receive a third. The overall one-year continuation rate was 23%. No significant differences in continuation rates were found based on age, race or payment type.

Entities:  

Keywords:  Americas; Colorado; Contraception; Contraception Continuation; Contraceptive Agents; Contraceptive Agents, Female; Contraceptive Agents, Progestin; Contraceptive Methods; Contraceptive Usage; Depo-provera; Developed Countries; Family Planning; Injectables; Medroxyprogesterone Acetate; North America; Northern America; Research Report; United States

Mesh:

Substances:

Year:  1996        PMID: 8959418

Source DB:  PubMed          Journal:  Fam Plann Perspect        ISSN: 0014-7354


  8 in total

1.  Complex decisions: correlates of injectable contraceptive discontinuation following HIV-1 seroconversion in an HIV prevention trial.

Authors:  Margaret R Caplan; Raphael J Landovitz; Thesla Palanee-Phillips; Gonasagrie Nair; Felix Mhlanga; Jennifer E Balkus; Sharon A Riddler; Pamina M Gorbach
Journal:  AIDS Care       Date:  2019-02-13

2.  One-year contraceptive continuation and pregnancy in adolescent girls and women initiating hormonal contraceptives.

Authors:  Tina R Raine; Anne Foster-Rosales; Ushma D Upadhyay; Cherrie B Boyer; Beth A Brown; Abby Sokoloff; Cynthia C Harper
Journal:  Obstet Gynecol       Date:  2011-02       Impact factor: 7.661

3.  Continuation and satisfaction of reversible contraception.

Authors:  Jeffrey F Peipert; Qiuhong Zhao; Jenifer E Allsworth; Emiko Petrosky; Tessa Madden; David Eisenberg; Gina Secura
Journal:  Obstet Gynecol       Date:  2011-05       Impact factor: 7.661

4.  Contraceptive adherence among HIV-infected women in Malawi: a randomized controlled trial of the copper intrauterine device and depot medroxyprogesterone acetate.

Authors:  Lisa B Haddad; Carrie Cwiak; Denise J Jamieson; Caryl Feldacker; Hannock Tweya; Mina Hosseinipour; Irving Hoffman; Amy G Bryant; Gretchen S Stuart; Isaac Noah; Linly Mulundila; Bernadette Samala; Patrick Mayne; Sam Phiri
Journal:  Contraception       Date:  2013-08-23       Impact factor: 3.375

5.  Safety and tolerability of depot medroxyprogesterone acetate among HIV-infected women on antiretroviral therapy: ACTG A5093.

Authors:  D Heather Watts; Jeong-Gun Park; Susan E Cohn; Song Yu; Jane Hitti; Alice Stek; Pamela A Clax; Laila Muderspach; Juan J L Lertora
Journal:  Contraception       Date:  2007-12-21       Impact factor: 3.375

6.  Contraceptive discontinuation and switching among couples receiving integrated HIV and family planning services in Lusaka, Zambia.

Authors:  Lisa Haddad; Kristin M Wall; Bellington Vwalika; Naw Htee Khu; Ilene Brill; William Kilembe; Rob Stephenson; Elwyn Chomba; Cheswa Vwalika; Amanda Tichacek; Susan Allen
Journal:  AIDS       Date:  2013-10       Impact factor: 4.177

7.  Preferences for a potential longer-acting injectable contraceptive: perspectives from women, providers, and policy makers in Kenya and Rwanda.

Authors:  Elizabeth E Tolley; Kevin McKenna; Caroline Mackenzie; Fidele Ngabo; Emmanuel Munyambanza; Jennet Arcara; Kate H Rademacher; Anja Lendvay
Journal:  Glob Health Sci Pract       Date:  2014-03-26

8.  Predictors of DMPA-SC continuation among urban Nigerian women: the influence of counseling quality and side effects.

Authors:  Jenny Liu; Jennifer Shen; Nadia Diamond-Smith
Journal:  Contraception       Date:  2018-05-04       Impact factor: 3.375

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.